Nasdaq:SAVA
CASSAVA SCIENCES INC
A clinical-stage biopharma firm developing anti-amyloid therapies for Alzheimer's disease with significant cash reserves but no current commercial revenue.
Key Metrics
Investment Thesis
Bull Case
Investors may view Cassava Sciences as a high-risk, high-reward opportunity given its robust cash position exceeding $120M which supports continued clinical development without immediate need for dilutive fundraising. The potential approval of an effective anti-amyloid therapy could generate massive value upon commercial launch, creating significant upside if the lead candidate succeeds in pivotal trials.
Bear Case
The stock carries extreme risk as the company generates zero revenue and has a material accumulated deficit of over $400M, indicating a complete reliance on external capital for survival. Recent regulatory scrutiny and potential data integrity issues surrounding its lead drug pose existential threats that could prevent product approval or result in severe legal penalties.
About CASSAVA SCIENCES INC
Cassava Sciences Inc. is a clinical-stage biotechnology company focused on developing novel treatments for neurological diseases, with its primary pipeline centered on anti-amyloid antibodies for Alzheimer's disease. The company operates primarily in the United States market through its proprietary therapeutic platform, leveraging extensive preclinical and early clinical data to advance its lead candidates.
Analysis
Management Discussion
Despite a reduction in net losses to $24.3M in 2024 compared to previous years of $97.2M and $76.2M, the company continues to operate at a loss driven by substantial operating expenses and R&D investments. The positive cash flow from financing activities indicates reliance on equity issuance to fund operations rather than commercial product sales.
Industry Overview
The Alzheimer's disease therapeutics market is highly competitive with billions in annual sales from current treatments, though new mechanisms of action are desperately needed. Regulatory pathways for anti-amyloid therapies have become more stringent following safety concerns and mixed clinical trial results from major competitors recently.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $80.0M | $106.0M | $141.4M |
| Operating Income | $-80.0M | $-106.0M | $-141.4M |
| R&D | — | $89.4M | $69.6M |
| G&A | $12.0M | $16.5M | $71.8M |
| Stock-Based Comp | $2.1M | $4.6M | $16.3M |
| Depreciation | $804.0K | $1.1M | $952.0K |
| Amortization | $497.0K | $446.0K | $180.0K |
| Other OpEx | $68.0M | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Pre-Tax Income | $-80.0M | $-106.0M | $-141.4M |
| Income Tax | $-3.8M | $-8.7M | $0 |
| Continuing Ops | $-76.2M | $-97.2M | $-141.4M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-76.2M | $-97.2M | $-24.3M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-76.2M | $-97.2M | $-24.3M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $211.2M | $129.6M | $136.5M |
| Cash & Equivalents | $201.0M | $121.1M | $128.6M |
| Prepaid Expenses | $10.2M | $8.5M | $8.0M |
| Other Current Assets | $0 | $0 | $0 |
| Long-Term Assets | $23.6M | $22.0M | $21.0M |
| PP&E (Net) | $22.9M | $21.9M | $21.0M |
| Intangibles | $622.0K | $176.0K | $37.0K |
| Operating Leases | $122.0K | $0 | — |
| Other LT Assets | $0 | $0 | $0 |
| Total Assets | $234.8M | $151.7M | $157.5M |
| Current Liabilities | $7.1M | $14.2M | $11.8M |
| Accounts Payable | $4.0M | — | — |
| Current Leases | $104.0K | $0 | — |
| Other Current Liab | $662.0K | $14.2M | — |
| Long-Term Liabilities | $232.0K | $0 | $79.0K |
| LT Operating Leases | $35.0K | $0 | — |
| Other LT Liab | $197.0K | $0 | — |
| Total Liabilities | $7.3M | $14.2M | $11.8M |
| Shareholders' Equity | $227.5M | $137.5M | $145.7M |
| Paid-In Capital | $511.0M | $518.2M | $550.8M |
| Retained Earnings | $-283.6M | $-380.8M | $-405.1M |
| Total L&E | $234.8M | $151.7M | $157.5M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-76.2M | $-97.2M | $-24.3M |
| Non-Cash Adjustments | $5.7M | $10.3M | $-90.3M |
| Working Capital Changes | $-7.0M | $4.9M | $-2.3M |
| Cash from Operations | $-77.5M | $-82.0M | $-116.9M |
| Capital Expenditures | $2.7M | $414.0K | $103.0K |
| Cash from Investing | $-2.7M | $-414.0K | $-103.0K |
| Cash from Financing | $47.8M | $2.6M | $124.5M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-32.4M | $-79.9M | $7.4M |
| Beginning Cash | $233.4M | $201.0M | $121.1M |
| Ending Cash | $201.0M | $121.1M | $128.6M |
Frequently Asked Questions
How does CASSAVA SCIENCES INC make money?
The company's operations are consolidated into a single segment focused on drug discovery and development, specifically targeting neurodegenerative disorders. Financials show heavy investment in research and development ($69.6M) and general administrative costs ($71.8M), with zero reported revenue or cost of goods sold from commercial sales.
What are the main risks for SAVA?
The company faces significant financial risk due to accumulated retained earnings deficits and no current revenue stream. Regulatory approval uncertainty remains a major threat given the controversial history of its lead drug and ongoing investigations into clinical data integrity. Potential liability from adverse patient events in early trials could impact future financing capabilities. Market competition is intense with multiple established players developing Alzheimer's therapeutics.
What is SAVA's competitive advantage?
The company possesses a strong balance sheet with over $128M in cash and equivalents, providing substantial runway for clinical trials. Its proprietary lead candidate has demonstrated preclinical efficacy in reducing amyloid plaques, offering a differentiated mechanism of action compared to existing market therapies.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.